# A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Patients

> **NCT01391013** · PHASE2 · COMPLETED · sponsor: **Janssen-Cilag S.p.A.** · enrollment: 30 (actual)

## Conditions studied

- Human Immunodeficiency Virus 1

## Interventions

- **DRUG:** Darunavir(DRV)
- **DRUG:** Ritonavir
- **DRUG:** 2 nucleoside reverse transcriptase inhibitors (NRTIs)

## Key facts

- **NCT ID:** NCT01391013
- **Lead sponsor:** Janssen-Cilag S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2013-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01391013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01391013, "A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01391013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*